ArticleJournal of microscopy and ultrastructure
Cell of Origin Classification of Diffuse Large B-Cell Lymphoma.
Article in Journal of microscopy and ultrastructure. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Emerging Roles of MicroRNAs in Diffuse Large B-Cell Lymphoma: From Molecular Mechanisms to Clinical Translation, Liquid Biopsy, and Precision Medicine.Biomedicines · 2026Review
- Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.European journal of haematology · 2026Review
- A DLBCL Prognostic model superior to the IPI score: Mechanistic study and clinical validation based on RFC2- and RFC4-mediated DNA damage repair.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of medium-to-large B lymphoid cells with diffuse growth patterns. Although it is a potentially curable disease, around 40% of the cases are either refractory to primary treatment or relapse. Based on gene expression profiling (GEP), DLBCL can be classified as germinal center B-cell subtype (GCB) and activated B-cell subtype (ABC). About 10%-15% of cases do not convincingly fall into either of the two subtypes and hence remain unclassified. Most widely used and suggested by WHO is Hans algorithm comprising immunohistochemical markers CD10, B-cell lymphoma6 (BCL6), and IRF4/MUM1, which classifies CD10+ and CD10-/BCL6+/MUM1-DLBCL as GCB, while CD10-/BCL6+/MUM1 + and BCL6-DLBCL as non-GCB. Aims: The aim of this study was to classify DLBCL into GCB and non-GCB subtypes using Hans Algorithm. Settings and Design: This was a retrospective study. Materials and Methods: Twenty-eight histologically diagnosed cases of nodal (71.4%), as well as extranodal (28.6%) DLBCL, were taken over the period of 2 years with age ranging between 10 and 65 years with 19 males and 9 females. M: F = 2.1:1. Depending upon the site involved, a primary panel of immunohistochemistry (IHC) markers, namely CD20, CD3, LCA, EMA, and CK, followed by a secondary panel comprising CD10, CD19, CD30, LMP1, BCL2, BCL6, MUM1, MYC, and FOXP1 was used. Results: In this study, it was found that the non-GCB subtype was more common than the GCB subtype in Indian population. Conclusions: Although the gold standard of GEP to assign cells of origin is using RNA microarray analysis, however, due to resource constraints and other limitations such as long turnaround times, IHC is the next acceptable alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.